Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Part of paid clinical trials in Fort Smith, Arkansas.

Sponsor
Tempus AI
Study ID
NCT05234177
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Observation — OTHER
    No intervention

Study Details

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Key Dates

Start date
Jun 21, 2022
Status verified
May 2025
Primary completion
Feb 28, 2027
Completion
Feb 28, 2029

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Participants with stage I-IV colorectal cancer (CRC)
    This protocol will include participants with stage I-IV CRC who are scheduled to undergo or have undergone a surgical resection with curative intent.

Primary Outcome Measure

Recurrence-Free Survival [ Time Frame: 2 years ]

Central Contacts

Locations (20)

FacilityCityStateZIPSite coordinators
Mercy Clinic Oncology - Fort SmithFort SmithArkansas72903
Aswanth Reddy, MD (PRINCIPAL_INVESTIGATOR)
MemorialCareFountain ValleyCalifornia92708
Laura Macias
562.706.2701
Amol Rao, MD (PRINCIPAL_INVESTIGATOR)
The Center for Cancer and Blood DisordersBethesdaMaryland20817
Kosunique Jenkins
301-571-2016
Mark Goldstein, MD (PRINCIPAL_INVESTIGATOR)
Mercy Clinic Oncology and Hematology - JoplinJoplinMissouri64804
Cynthia Meyer
Samir Dalia, MD (PRINCIPAL_INVESTIGATOR)
Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer CenterSpringfieldMissouri65804
Jennifer Hylton
Mohan Tummala, MD (PRINCIPAL_INVESTIGATOR)
Mercy Clinic Oncology and Hematology - David C. Pratt Cancer CenterSt LouisMissouri63141
Bethany Sleckman, MD (PRINCIPAL_INVESTIGATOR)
Mercy Clinic Oncology and Hematology - Sindelar Cancer CenterSt LouisMissouri63128
Jessica Black
Yifan Tu, MD (PRINCIPAL_INVESTIGATOR)
Washington University School of MedicineSt LouisMissouri63110
Mary Pecoraro
314-273-0884
Ryan Fields, MD (PRINCIPAL_INVESTIGATOR)
Nebraska Cancer SpecialistsOmahaNebraska68130
Brenda Broekemeier
308-218-6324
Timothy Huyck, MD (PRINCIPAL_INVESTIGATOR)
Southeastern Medical Oncology CenterGoldsboroNorth Carolina27543
Jennifer Fields
919-587-9084
Samer Kasbari, MD (PRINCIPAL_INVESTIGATOR)
Aultman HospitalCantonOhio44710
Kristin Shine
Adarsh Vennepureddy, MD (PRINCIPAL_INVESTIGATOR)
TriHealth Cancer InstituteCincinnatiOhio45220
Wayne Thompson
513-865-5020
Benjamin Kuritzky, MD (PRINCIPAL_INVESTIGATOR)
Ohio State UniversityColumbusOhio43210
Jennifer Moon
Arjun Mittra, MD (PRINCIPAL_INVESTIGATOR)
OhioHealth Research InstituteColumbusOhio43214
Kevin Miller
614-788-3886
Arvinder Bhinder, MD (PRINCIPAL_INVESTIGATOR)
Toledo Clinic Cancer CenterToledoOhio43623
Pam Shoup
419-214-4236
John Nemunaitis, MD (PRINCIPAL_INVESTIGATOR)
Mercy Clinic Oncology and Hematology - ColettaOklahoma CityOklahoma73120
Patricia Strubhar
Carla Kurkjian, MD (PRINCIPAL_INVESTIGATOR)
Cancer Care Associates of YorkYorkPennsylvania17403
Jennifer Stough
717-741-9229
Chanh Huynh, MD (PRINCIPAL_INVESTIGATOR)
Utah Cancer SpecialistsSalt Lake CityUtah84124
Angela Nuttall
801-267-5606
Kyle Kitchen, Pharm-D (PRINCIPAL_INVESTIGATOR)
University of Washington / Fred Hutchinson Cancer CenterSeattleWashington98109
Bentina Marin
Stacey Cohen, MD (PRINCIPAL_INVESTIGATOR)
ThedaCare Regional Cancer CenterAppletonWisconsin54911
Rachel Luedtke
920-364-3616
Matthias Weiss, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Fort Smith, AR

By condition

Related Studies